摘要
目的:研究齐拉西酮对精神分裂症认知功能的影响。方法:开放、前瞻性研究设计。将60例符合CCMD-3精神分裂症诊断标准的女性患者纳入研究组。齐拉西酮起始剂量为40 mg/日,2周内加到治疗量,最大量为160 mg/日。观察周期均为8周。在治疗前及治疗后进行阳性与阴性症状量表(Positive and Negative Syndrome Scale,PANSS)评定、探究性眼球运动测试(Exploratory Eye Movement,EEM)、注意力划销测验(Cancellation Test,CT)、威斯康星卡片分类测验(Wisconsin Card Sorting Test,WCST)。所有数据输入SPSS 17.0统计软件处理。结果:治疗8周后,反应性探索分增加(responsive search score RSS)(P=0.01),判别式D值降低(P=0.008);注意力划销测验的总分增加(P=0.001);威斯康星卡片分类测验显示,完成分类数(CC)、正确应答数(RC)、正确应答百分比(RCP)、错误应答数(RE)、完成第一个分类所需应答数(RF)有显著性差异(P<0.05),概念化水平百分数(RFP)、持续性应答数(RP)、持续性错误数(RPE)、持续性错误的百分数(RPEP)、不能维持完整分类数(规则坚持失败FM)有非常显著性差异(P≤0.005)。治疗后阳性与阴性症状量表均显著改善(P=0.000)。相关分析发现,治疗前注意力划销测验(CT)总分与阴性症状明显负相关,D值与阳性症状及阴性症状显著正相关。治疗后完成分类数与阳性症状及阴性症状显著负相关。结论:齐拉西酮能有效改善女性精神分裂症患者的精神症状及认知功能。
Objective：To study the cognitive effects of ziprasidone with female schizophrenia.Methods：A total of 60 female patients with schizophrenia,who were up to standard of CCMD-3,were randomly assigned to ziprasidone group（n=60） for 8 weeks.The dosage of ziprasidone was 40mg/day to 160mg/day.To make positive and negative syndrome scale（PANSS）,as well as exploratory eye movement（EEM）,cancellation test（CT）,wisconsin card sorting test（WCST）,before and after the cure of 8 weeks.All the datum was put into spss17.0 to dispose.Results： After treatment eye fixations（NEF）increased but had no statistic meaning,RSS increased（P=0.01）,D decreased（p=0.008）;the total score of CT was increased（P=0.0001）;in WCST,CC,RC,RCP increased（P〈0.05）,RE decreased（P〈0.05）,RFP increased（P〈0.01）,RP,RPE,RPEP decreased（P〈0.01）.After 8 weeks,PSP and PANSS score increased（P=0.000）.Conclusions： ziprasidone is effective in the treatment of schizophrenia,and more effective with the cognitive of schizophrenia also.
出处
《中国民康医学》
2012年第7期778-781,共4页
Medical Journal of Chinese People’s Health
